Oral Rehydration SolutionContaining Amylase Resistant Starch in Severely Malnourished Children.
NCT00324285 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180
Last updated 2017-11-28
Summary
Severe malnutrition is associated with a high rate of mortality, even when using the latest WHO recommendations. Watery diarrhea as observed in cholera is an additional vital risk to those children. The fragility of the children together with the complexity of the pathophysiology and the simplicity of the medical environment where the treatment is delivered are serious constraints for the development of new therapies. Dehydration is a special immediate risk in those children who already displayed altered body distribution of water with potassium, magnesium, zinc and other nutrient deficiency. Dehydration is also often associated with a decrease in appetite. In addition, the intestinal function is altered both by the infectious agent and the nutritional status of the child. Recommended therapy for those children comprises oral rehydration with ReSoMaL (modified ORS for use in severely malnourished children recommended by WHO), at a relatively low rate, with permanent monitoring; in addition, breastfeeding should not be interrupted and feeding with F100 (Milk based formula diet for use in severely malnourished children recommended by WHO) is recommended. Recently, amylase-resistant starch added to a standard WHO-ORS has been shown to reduce the duration and severity of adults with cholera. The rationale for using amylase-resistant starch was that when starch enters the colon it is metabolized by the bacteria. The short-chain fatty acids thus produced stimulate sodium absorption in the colon, just like glucose stimulates water absorption in the small intestine. In addition, this treatment would be of particular interest in malnutrition because short-chain fatty acids are specific energetic substrate for the colon.In the present project, we propose to test the hypothesis that addition of amylase-resistant starch to the already recommended treatment of severely malnourished children with cholera reduces the severity and duration of diarrhea; this could be achieved through the effect of short-chain fatty acids on colonic sodium absorption. In addition, a better recovery from malnutrition could be achieved through the energy provided by short-chain fatty acids to the colon and improved appetite through improved rehydration. Thus, the aim of the study is to measure the effect of amylase-resistant starch added to an already accepted treatment (with minimal changes) at the rehydration and rehabilitation phases of the treatment. A total of 210 children aged 6 mo to 60 mo will be studied in three groups : a) glucose based ORS and amylase-resistant starch; b) glucose based ORS without amylase resistant starch ; c) rice based ORS . The major outcome variables on the first phase (diarrhoeal duration and stool output), and second phase (food intake, weight gain) will be compared between the two treatment groups. The result of the study if found effective in reducing the duration of diarrhoea, enhance recovery from diarrhoea and malnutrition in severely malnourished children, will contribute to better case management of these children.
Conditions
- Diarrhoea
- Severe Malnutrition
Interventions
- DRUG
-
Amylase resistant starch added ORS
Sponsors & Collaborators
-
Nestlé Foundation
collaborator OTHER -
International Centre for Diarrhoeal Disease Research, Bangladesh
lead OTHER
Principal Investigators
-
Nur H Alam, MD · International Centre for Diarrhoeal Disease Research, Bangladesh
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 6 Months
- Max Age
- 36 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-07-31
- Primary Completion
- 2005-06-30
- Completion
- 2005-06-30
Countries
- Bangladesh
Study Locations
More Related Trials
-
High/Low Dose Vit A in Diarrhea/ALRI in Severe PEM
NCT00388921 ·Status: COMPLETED ·Phase: NA
-
Effects of Recto-colic Enemas of Butyrate on the Digestive Disorders of Very Low Birth Weight Preterms <1250 Grams
NCT01536483 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Community Based Prevention of Rotavirus Gastroenteritis by a Functional Food Supplement
NCT01265355 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effectiveness of Folic Acid Supplementation in Acute Watery Diarrhea Among Children Under 5 Years of Age
NCT04782037 ·Status: UNKNOWN ·Phase: PHASE4
-
Metronidazole Pharmacokinetics (PK) in Premature Infants
NCT01222585 ·Status: COMPLETED ·Phase: PHASE1
-
Intratracheal Vitamin A Administration With Surfactant for Newborn Respiratory Distress Syndrome
NCT01265589 ·Status: UNKNOWN ·Phase: PHASE3
-
Nutritional Management of Children With Chronic Diarrhea
NCT01812629 ·Status: COMPLETED ·Phase: NA
-
Three Dietary Regimens in Pre-colonoscopic Bowel Preparation in Children
NCT05609591 ·Status: COMPLETED ·Phase: NA
-
The Effect of Amoxicillin Versus Placebo on Gastrointestinal Motility in Children
NCT01530009 ·Status: COMPLETED ·Phase: NA
-
Domperidone in Refractory Gastroparesis
NCT00760461 ·Status: TERMINATED ·Phase: PHASE2
-
Effect of Vitamin A in the Treatment of Neonatal Sepsis and Necrotizing Enterocolitis
NCT00707785 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics of Enteral Omeprazole Suspension in Patients With Cerebral Palsy and Mental Retardation
NCT00426595 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison Between Oral and Enema of Chloral Hydrate
NCT03242629 ·Status: COMPLETED ·Phase: NA
-
Prescription Pattern of Adjuvant Drugs and Vitamins in Patients Undergoing Long-term Home Nutritional Support for Intestinal Insufficiency
NCT01696656 ·Status: COMPLETED
-
Intestinal Permeability in Preterm Infants
NCT01756040 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Cow Milk and 15% Hypertonic Saline in the Treatment of Rectal Prolapse in Children
NCT06174584 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Improved Quality of Life in Children With Intestinal Failure
NCT04981262 ·Status: COMPLETED ·Phase: NA
-
Obeticholic Acid in Pediatric Subjects With Biliary Atresia
NCT05321524 ·Status: TERMINATED ·Phase: PHASE2
-
Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
NCT00226044 ·Status: COMPLETED ·Phase: PHASE3
-
Use of Tocofersolan (Vedrop®) to Prevent or Treat Refractive Vitamin E Deficiency in Infants and Children
NCT03582384 ·Status: WITHDRAWN ·Phase: PHASE2
-
Protease Activated Receptor-2 and Gastrointestinal Dysfunction in Critical Illness
NCT03011151 ·Status: COMPLETED
-
Metoclopramide Use in Very Low Birth Weight Newborns
NCT00242450 ·Status: COMPLETED ·Phase: PHASE4
-
Nutritional Management of Infants With Chronic Diarrhea
NCT01820494 ·Status: COMPLETED ·Phase: NA
-
Nutrition Support for Hirschsprung Disease
NCT04598841 ·Status: COMPLETED ·Phase: NA
-
Tolerance of an Oral Nutritional Supplement(ONS)
NCT01782456 ·Status: COMPLETED ·Phase: NA